Kynexis is advancing precision therapeutics for brain diseases by taking a biomarker-based approach to advance a potential first-in-class treatment for cognitive impairment associated with schizophrenia (CIAS). By harnessing large data to identify and stratify patients based on the underlying causal human.  biology of the disease, Kynexis is targeting KAT-II, a key enzyme in the kynurenine pathway. The company’s lead candidate, KYN-5356, is a first-in-class small molecule that is potent and highly selective for KAT-II. 

Biotechnology

Life Sciences

Therapeutics

Kynexis

Kees Been

Thomas Gundelund Rasmussen

Christer Köhler

Thomas Rasmussen

Nancy Van Osselaer

Francis Mcmahon

Dennis Murphy

Leadership Team

Clinical Development Team

Teams at Kynexis

Leadership Team

Clinical Development Team